Ask HopeStage to review this study with me
Study ID: NCT02827513. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT02827513
Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
This study has public registry information in Australia. It focuses on Adult Attention-deficit Hyperactivity Disorder.
ADHDDrugFrom 18 Years to 45 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing ADHD.
What would participation involve?
Participants may receive a study medication, attend study visits with the research team. The registry lists locations in Australia.
Who is it mainly for?
This study appears to be mainly for adults with ADHD.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a lab. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to follow the planned visits or tasks and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first and other treatments that could interfere with the study. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateDecember 2015
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Australia
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02827513
- Official title
- A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT02827513. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Australia.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with adhd; age range: From 18 Years to 45 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingISRCTN85247318
Brain stimulation in adults with attention deficit hyperactivity disorder
This study is recruiting in Australia. It is testing brain stimulation for ADHD.
RecruitingISRCTN68819261
Can a sleep intervention improve outcomes for children with attention-deficit hyperactivity disorder (ADHD)?
This study is recruiting. It focuses on ADHD and currently lists participation information in Australia.
RecruitingISRCTN33930984
Does the identification and treatment of comorbid anxiety disorders in children with attention deficit hyperactivity disorder (ADHD) improve outcomes?
This study is recruiting in Australia. It focuses on ADHD.